In addition, the fusion proteins of anti-EGFR nanobodies were conjugated with glycosylphosphatidylinositol (GPI)-anchor signal peptides to induce the targetability of exosomes to EGFR-expressing tumor cells [94]. This evidence concerns the gene EGFR and neoplasm.